Introduction: Whether immunohistochemical staining of programmed death ligand 1 (PD-L1) on cells of pleural effusion could be used to predict response to immunotherapy treatment has not been reported.
Introduction
Immune checkpoint inhibitors have become one of the treatment options for lung cancer. However, it is still difficult to predict the response of patients with lung cancer to immunotherapy. KEYNOTE 010 and KEYNOTE 024 revealed that the survival benefit was related to the expression of programmed death ligand 1 (PD-L1) on tumor cells. 1, 2 Other studies showed that PD-L1 expression on tumor cells and tumor-infiltrating immune cells predicted the response to immunotherapy.
response to immunotherapy suggests that more understanding of cancer immunity is needed.
Malignant pleural effusion is a common complication of lung cancer. Chen et al. reported that tumor-induced immunosuppression could be observed in pleural effusion. 4 However, PD-L1 expression in pleural effusion cells has not been reported. The aim of our study was to find the PD-L1 expression in tumor cells, immune cells, and macrophages from malignant pleural effusion, which may represent the microenvironment of lung cancer.
Materials and Methods

Study Design and Patients
We retrospectively reviewed patients with lung cancer who underwent pleural effusion thoracocentesis between 2014 and 2016 at Taipei Veterans General Hospital. To evaluate the effects of immunotherapy, we retrospectively reviewed the cohorts from different perspectives. The study was approved by the Institutional Ethical Review Board of Taipei Veterans General Hospital (VGHIRB No. 2016-06-007A).
Efficacy Evaluation
Chest computed tomography was performed within 3 weeks before treatment and every 2 to 3 months thereafter. The treatment response was assessed by using the Response Evaluation Criteria in Solid Tumors (version 1.1). 5 Progression-free survival (PFS) with immunotherapy was defined as the duration from the date of initiation of immunotherapy to the earliest sign of disease progression or death from any cause. If disease progression had not occurred by the time of the last follow-up, PFS was considered to be censored. Overall survival (OS) was defined as the period from the beginning of immunotherapy to the date of death. OS was censored for those patients who were still alive.
Cell Block Preparation
For cell block preparation, a total of 30 to 50 mL of pleural fluid was centrifuged at 1500 rpm for 5 minutes. The sediment was mixed with 100% ethyl alcohol and centrifuged. The cell pellets were subsequently formalinfixed, dehydrated, and embedded in paraffin. Finally, the paraffin blocks were cut into 4-mm sections for hematoxylin and eosin staining and immunohistochemistry (IHC).
PD-L1 Evaluation
Each tissue section, 4-mm in thickness, was deparaffinized and stained for PD-L1 expression by using two different antibody clones. One was a rabbit anti-human PD-L1 monoclonal antibody (clone SP142 [Spring Bioscience, Pleasanton, CA) performed on the Leica BOND-MAX automatic staining system (Leica Biosystems, Nussloch, Germany) at a 1:100 dilution, and the other was the PD-L1 IHC 22C3 pharmDx Kit (clone 22C3 [DAKO, Carpinteria, CA]) performed on Dako Autostainer Link 48 platform with a validated and automated staining protocol. The nuclei in the tissue sections were counterstained with hematoxylin. Human tonsil tissue was used as a positive control for PD-L1 staining. The scoring of the PD-L1 expression of tumor cells and inflammatory cells (macrophages and lymphocytes) within the tissue was included. Immunoreactivity was scored as 0 for absence and 1þ for faint, 2þ for moderate, and 3þ for intense membranous staining (Fig. 1 ).
EGFR Mutation Analysis
All the specimens were from the main tumor biopsy or pleural effusion cell block. Tumor EGFR mutations were analyzed by cobas 4800 EGFR mutation assay (Roche, Molecular Diagnostics, Pleasanton, CA), which utilized a real-time polymerase chain reaction-based technology.
Statistical Analysis
All categorical variables were analyzed by using x 2 tests and Pearson's correlation. Two-sided t-tests were used for continuous variables. All statistical analyses were performed with SPSS software, version 19.0 (IBM Corp, Armonk, NY).
Results
Patients
From 2014 to 2016, we collected 119 cell blocks; 102 had enough cells for PD-L1 IHC stain. All cell blocks were reviewed by an experienced pathologist. They included blocks from 12 patients who had received immunotherapy. We collected their previous main tumor specimens and performed IHC staining for all of them.
Intensity of PD-L1 Expression
Cytologic examination of the 102 cell blocks revealed that the PD-L1 intensity in tumor cells of 84 of them (82.4%), macrophages of 78 of them (76.5%), and immune cells of 97 of them (95.7%) was grade 0. Grade 1 intensity was found in the tumor cells of seven cell blocks (6.9%), macrophages of 24 (23.5%), and immune cells of one (1.0%). Tumor cells in six (5.9%) had a grade 2 intensity of PD-L1 expression; grade 3 intensity of PD-L1 was expressed in tumor cells of five cell blocks (4.9%) and immune cells of four (3.9%) ( Table 1) .
The intensity of PD-L1 expression between tumor cells and macrophages was correlated (p < 0.001). Examination of the PD-L1 intensity between tumor cells and immune cells and between macrophages and immunes cell did not reveal a correlation (p ¼ 0.162 and p ¼ 0.120, respectively) ( Table 2) .
Clinicopathological Characteristics
Female patients had a higher proportion of grade 0 PD-L1 intensity in tumor cells than did male patients (p ¼ 0.012). However, differences did not show in macrophages and immune cells (p ¼ 0.519 and p ¼ 0.430, respectively). Patients who were never-smokers also expressed more grade 0 PD-L1 intensity in tumor cells than did those who were ever-smokers or current smokers (p ¼ 0.032). Differences did not occur in macrophages and immune cells either (p ¼0.907 and 0.476, respectively). The PD-L1 intensities of tumor cells were different in patients with different Eastern Cooperative Oncology Group performance status (ECOG PS), but no differences were found in the PD-L1 intensities of their macrophages or immune cells. EGFR mutation status and age were significantly different among the different PD-L1 intensity groups for tumor cells, macrophages, and immune cells (Supplementary Tables 1-3 ). Different intensities of PD-L1 expression in tumor cells and macrophages were not associated with OS of patients (p ¼ 0.235). Nevertheless, different intensities of PD-L1 expression in immune cells were associated with OS of patients (p ¼ 0.004) (Supplementary Figs. 1-3 ).
Patients Who Received Immunotherapy
A total of 12 patients in this study had undergone immunotherapy. Among them, five patients had stable lung cancer, six had progression, and one was lost. PD-L1 expression was absent in the main tumor of all 12 patients using either 22C3 or SP142 IHC stain. As for malignant pleural effusion, PD-L1 expression was absent in 11 patients and faint in one patient using 22C3 IHC stain. The SP142 IHC stain results for tumor cells, macrophages, and immune cells were not significantly different between the response group and the nonresponse group ( (Fig. 2) .
Discussion
The microenvironment model of malignant pleural effusion has not been established. Lievense et al. focused on the malignant pleural effusion of mesothelioma and found that macrophages, especially the tumor-promoting M2 phenotype, hampered the antitumor immune response of T cells. 6 According to previous studies, PD-L1 expression induced macrophages toward the M1 phenotype. 7, 8 In our study, most macrophages did not express or only faintly expressed PD-L1. This is a hint that M2 macrophages play a key role in the microenvironment of malignant pleural effusion.
PD-1 receptor is a T-cell-coinhibitory protein that selectively binds to PD-L1, which is usually expressed on tumor cells. 9 This pathway negatively regulates T-lymphocyte activation and down-regulates its antitumor activity. 10 The PD-L1 expression of tumor cells is the most frequently used marker to predict efficacy of immune checkpoint inhibitors. Many studies also use PD-L1 expression on immune cells to predict the activity of anti-PD-L1 antibodies. 3, 11 The POPLAR study showed that PD-L1 expression by tumor cells and tumor-infiltrating immune cells predicted the benefits of immune checkpoint inhibitors. 3 Nevertheless, the correlation between the PD-L1 expression of immune cells of malignant pleural effusion and anti-PD-L1 antibody or survival has not been studied. Our data showed that only a small amount of immune cells had intense PD-L1 expressions in malignant pleural effusion. In addition, our patients with a high intensity of PD-L1 expression in immune cells had significantly longer OS. Therefore, PD-L1 expression in the immune cells of pleural effusion could possibly predict the survival of patients. However, the correlations of PD-L1 expression in the main tumor and in malignant pleural effusion are still not clear.
The clinicopathological correlations between different types of PD-L1 expression in patients with lung cancer are still unclear. Some studies have reported poor correlation between PD-L1 expression and clinicopathological characteristics, including age, sex, smoking status, tumor size, and tumor stage. 12, 13 However, others have suggested that smoking status, male sex, adenocarcinoma, and poor differentiation may be associated with PD-L1 expression. 14, 15 In our data, different intensities of PD-L1 expression on macrophages and immune cells were not correlated with sex, ECOG PS, EGFR mutation status, or age. However, sex, smoking status, and ECOG PS differ significantly between different PD-L1 expression groups in tumor cells of malignant pleural effusion.
In summary, the low intensity of effusion immune cell PD-L1 expression is associated with the poor survival of patients with lung cancer with malignant pleural effusion.
